What is CALC's current stock price?

CALC (CalciMedica, Inc.) is currently trading at $0.97 with a market cap of $15.3M.

What sector is CalciMedica, Inc. in?

CalciMedica, Inc. (CALC) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CALC a good stock to buy?

Analysts have a Buy consensus on CALC with a price target of $266.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

Back to Market返回行情

CALC CalciMedica, Inc.

USHealthcare

$0.9654-7.17%ClosedMarket Cap: $15.3M

As of 2026-07-02

Why CALC matters now

CalciMedica, Inc. (CALC) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.97 with -7.17% on the session and $15.3M in market capitalization; recent performance reads 1-month +22.35% and YTD -88.54%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $5.0M, and EPS of $0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -177.4%.

The latest indexable market news headline is "CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $392.00; recent insider activity includes Leheny A. Rachel filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

-10.27

P/S

0.00

EV/EBITDA

-0.21

DCF Value

$0.00

FCF Yield

-177.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

4093.0%

ROA

-227.0%

ROIC

-674.6%

Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0.00	$5.0M	$0.30
Q4 2025	$0.00	$-10.8M	$-0.72
FY 2025	$0.00	$-29.6M	$-1.97
Q3 2025	$0.00	$-7.8M	$-0.52

Analyst Ratings

Consensus

Buy

Target (Consensus)

$266.00

Target (Median)

$392.00

Target Range

$14.00 - $392.00

Strong Buy: 0Buy: 3Hold: 1Sell: 0Strong Sell: 0

OppenheimerOutperform

2026-03-05

HC Wainwright & Co.Neutral

2026-01-29

Trading Activity

Insider Trades

Leheny A. Racheldirector, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER

Sell2026-04-07

Stauderman Kenneth A.officer: Chief Scientific Officer

Sell2026-04-07

Dunn Michael J.officer: President and COO

Sell2026-04-07

Roberts Eric Wdirector, 10 percent owner, officer: CHIEF BUSINESS OFFICER

Sell2026-04-07

Hebbar Sudarshanofficer: Chief Medical Officer

Sell2026-04-07

Related Stocks

ATNM

Actinium Pharmaceuticals, Inc.

LAVA Therapeutics N.V.

$45.8M

MAIA

MAIA Biotechnology, Inc.

$82.7M

Latest News

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramPRNewsWire · 2026-06-24

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataPRNewsWire · 2026-06-24

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesPRNewsWire · 2026-05-12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.93

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.